These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7909490)

  • 1. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
    Têtu B; Brisson J
    Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study.
    Têtu B; Brisson J; Côté C; Brisson S; Potvin D; Roberge N
    Int J Cancer; 1993 Sep; 55(3):429-35. PubMed ID: 8397164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
    Allred DC; Clark GM; Tandon AK; Molina R; Tormey DC; Osborne CK; Gilchrist KW; Mansour EG; Abeloff M; Eudey L
    J Clin Oncol; 1992 Apr; 10(4):599-605. PubMed ID: 1548522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
    Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
    Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results.
    van Diest PJ; Baak JP; Matze-Cok P; Bacus SS
    Pathol Res Pract; 1992 Apr; 188(3):344-9. PubMed ID: 1378224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients.
    Lüftner D; Jung A; Schmid P; Geppert R; Kienle E; Wernecke KD; Possinger K;
    Breast Cancer Res Treat; 2003 Aug; 80(3):245-55. PubMed ID: 14503797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).
    Corte MD; Rodil JA; Vázquez J; García L; Rodríguez JC; Bongera M; Fernández JC; González LO; Lamelas ML; Allende M; García-Muñiz JL; Fueyo A; Vizoso FJ
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):701-14. PubMed ID: 16075281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node negative breast cancer without systemic adjuvant treatment (T1N0)].
    Göhring UJ; Aslan-Schadwinkel Y; Scharl A
    Geburtshilfe Frauenheilkd; 1993 Sep; 53(9):625-9. PubMed ID: 7901111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.